Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen

被引:6
|
作者
Trifunov, Selena [1 ,6 ]
Natera-de Benito, Daniel [1 ,2 ]
Carrera-Garcia, Laura [1 ,2 ]
Codina, Anna [1 ]
Exposito-Escudero, Jesica [1 ,2 ]
Ortez, Carlos [1 ]
Medina, Julita [4 ]
Torres Alcala, Soraya [3 ]
Bernal, Sara [5 ,6 ]
Alias, Laura [5 ,6 ]
Badosa, Carmen [1 ]
Balsells, Sol [7 ]
Alcolea, Daniel [3 ]
Nascimento, Andres [1 ,2 ,6 ]
Jimenez-Mallebrera, Cecilia [1 ,6 ,8 ]
机构
[1] Inst Recerca St Joan De Deu, Appl Res Neuromuscular Dis, Barcelona, Spain
[2] Hosp San Juan Dios, Dept Neurol, Neuromuscular Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona, Spain
[4] Hosp St Joan De Deu, Rehabil & Phys Unit Dept, Barcelona, Spain
[5] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Dept Genet, Barcelona, Spain
[6] Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain
[7] Inst Recerca St Joan De Deu, Stat Dept, Barcelona, Spain
[8] Univ Barcelona, Dept Genet Microbiol & Stat, Barcelona, Spain
关键词
Biomarkers; cerebrospinal fluid; nusinersen; response predictors; serum; spinal muscular atrophy; SHAM CONTROL; EXPRESSION; EXOSOMES;
D O I
10.3233/JND-230012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Three therapeutic strategies have radically changed the therapeutic scenario for spinal muscular atrophy (SMA). However, therapeutic response differs between individuals. There is a need to identify biomarkers to further assess therapeutic response and to better understand which variables determine the extent of response. Methods: We conducted a study using an optimized digital droplet PCR-based method for the ultra-sensitive detection of SMN transcript in serum EVs from SMA 2 individuals treated with nusinersen over 14 months. In parallel, we investigated levels of serum and CSF neurofilament heavy chain (pNF-H) in the same cohort. Results: Expression of flSMN transcript in EVs of SMA 2 individuals prior to nusinersen was lower than in controls (0.40 vs 2.79 copies/ul; p < 0.05) and increased after 14 months of nusinersen (0.40 vs 1.11 copies/ul; p < 0.05). The increase in flSMN with nusinersen was significantly higher in younger individuals (p < 0.05). Serum pNF-h was higher in non-treated individuals with SMA 2 than in controls (230.72 vs 22.88 pg/ml; p < 0.05) and decreased with nusinersen (45.72 pg/ml at 6 months, 39.02 pg/ml at 14 months). CSF pNF-h in SMA 2 individuals also decreased with nusinersen (248.04 pg/ml prior to treatment, 197.10 pg/dl at 2 months, 104.43 pg/dl at 6 months, 131.03 pg/dl at 14 months). Conclusions: We identified an increase of flSMN transcript in serum EVs of SMA 2 individuals treated with nusinersen that was more pronounced in the younger individuals. Our results indicate that flSMN transcript expression in serum EVs is a possible biomarker in SMA to predict or monitor the response to treatment.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 50 条
  • [31] SOCIETAL COSTS OF SPINAL MUSCULAR ATROPHY TYPE 1 FOR PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC OR NUSINERSEN IN THE UNITED KINGDOM
    Kleintjens, J.
    Patel, A.
    van Keep, M.
    Srivastava, K.
    McHale, P.
    Affinito, S.
    Bischof, M.
    VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
  • [32] Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1
    Fitzgerald, Dominic A.
    Doumit, Michael
    Abel, Francois
    PAEDIATRIC RESPIRATORY REVIEWS, 2018, 28 : 11 - 17
  • [33] Type 1 spinal muscular atrophy treated with nusinersen in Norway, a five-year follow-up
    Wik-Klokk, Merete
    Rasmussen, Magnhild
    Orstavik, Kristin
    Zetterberg, Henrik
    Hagen, Milada
    Holtebekk, Marie Elizabeth
    Ramm-Pettersen, Anette
    Wallace, Sean
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2024, 53 : 109 - 116
  • [34] Spinal muscular atrophy type I associated with a novel SMN1 splicing variant that disrupts the expression of the functional transcript
    Votsi, Christina
    Koutsou, Pantelitsa
    Ververis, Antonis
    Georghiou, Anthi
    Nicolaou, Paschalis
    Tanteles, George
    Christodoulou, Kyproula
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [35] A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3
    Cote, Isabelle
    Hodgkinson, Victoria
    Nury, Marianne
    Bastenier-Boutin, Louis
    Rodrigue, Xavier
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2025, 52 (01) : 119 - 128
  • [36] Use of Ommaya Reservoir with a Thoracic Spinal Catheter for Intrathecal Delivery of Nusinersen in a Patient with Spinal Muscular Atrophy Type 2
    Lakhotia, Arpita
    Bhalla, Sonam
    Doll, Elizabeth
    Gump, Willam
    NEUROLOGY, 2018, 90
  • [37] Risdiplam clinical trial outcomes in individuals with spinal muscular atrophy (SMA) and four SMN2 copies
    Toy, F.
    Bertini, E.
    Chiriboga, C. A.
    Mercuri, E.
    Dickendesher, T.
    Li, Y.
    Martin, C.
    Palfreeman, L.
    Tam, S.
    Yeung, W.
    ANNALS OF NEUROLOGY, 2025, 96 : S126 - S127
  • [38] Nusinersen Improves Motor Function in Type 2 and 3 Spinal Muscular Atrophy Patients across Time
    Cavaloiu, Bogdana
    Simina, Iulia-Elena
    Vilciu, Crisanda
    Traila, Iuliana-Anamaria
    Puiu, Maria
    BIOMEDICINES, 2024, 12 (08)
  • [39] Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen (vol 219, pg 223, 2020)
    Sansone, Valeria A.
    Pirola, Alice
    Albamonte, Emilio
    Pane, Marika
    Lizio, Andrea
    D'Amico, Adele
    Catteruccia, Michela
    Cutrera, Renato
    Bruno, Claudio
    Pedemonte, Marina
    Messina, Sonia
    Rao, Fabrizio
    Roma, Elisabetta
    Salmin, Francesca
    Coratti, Giorgia
    Di Bari, Alessandra
    De Sanctis, Roberto
    Pera, Carmela Maria
    Sframeli, Maria
    Piastra, Marco
    Macagno, Francesco
    Vita, Giuseppe
    Bertini, Enrico
    Mercuri, Eugenio
    JOURNAL OF PEDIATRICS, 2022, 246 : 292 - 292
  • [40] NUMBER NEEDED TO TREAT IN PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPE 1 TREATED WITH AVXS-101 RELATIVE TO NUSINERSEN
    Dabbous, O.
    Cloutier, M.
    Guerin, A.
    Pivneva, I
    Wu, E. Q.
    Sproule, D. M.
    VALUE IN HEALTH, 2018, 21 : S246 - S247